Webinar – Keeping Your Life Science Company in Compliance in China

December 16, 2011

Updating and Upgrading Your Regulatory and Anti-Corruption Compliance

In today’s aggressive compliance environment, it is crucial for life sciences companies to stay in full compliance with regulatory and anti-corruption requirements when developing and marketing their drugs, medical devices, and other products in China. In this 90-minute webcast, experts with hands-on experience will present the latest enforcement trends, case studies, and practical tips for compliance in China, focusing on these areas: 

  • Part I:  Complying with recent changes in SFDA regulatory requirements
         o Clinical trials
         o Pre-market approval
         o Sales and marketing
         o Post-approval safety risk management
  • Part II:  Complying with anti-corruption requirements in an aggressive enforcement environment
         o Specific corruption challenges faced by life science companies in China
         o FCPA and UK Bribery Act enforcement trends
         o Compliance with local PRC anti-corruption laws and enforcement trends
         o Practical tips for modifying compliance programs

Access this webinar by clicking on this link.